Tellgen Corporation

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
11.28 ^CNY	-0.27%		+0.53%	-36.09%

16/07	Tellgen Unit Gets License for Immunoassay Analyzers	MT
07/06	Shanghai Maishi Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation	CI

Shareholders Plan To Divest Stake In Tellgen

January 24, 2019 at 10:30 am IST

Tellgen Corporation (SZSE:300642) said its shareholders plan to cut stake up to 3% within six months.

Latest news about Tellgen Corporation

Tellgen Unit Gets License for Immunoassay Analyzers	16/07	MT
Shanghai Maishi Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation	07/06	CI
Tellgen Corporation Approves Cash Dividend for 2023	16/05	CI
Shanghai Maishi Biotechnology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation	14/05	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	06/05	CI
Tellgen Corporation's Equity Buyback announced on February 6, 2024, has closed with 1,946,150 shares, representing 1.2% for CNY 25.98 million.	05/05	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	22/04	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	01/04	CI
Tellgen Corporation announces an Equity Buyback for CNY 50 million worth of its shares.	06/02	CI
Tellgen Corporation authorizes a Buyback Plan.	06/02	CI
Tellgen Corporation Announces Board Appointments	27/12	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023	24/23/24	CI
Tellgen Corporation, Shanghai Tellgen Diagnostic Technology Co., Ltd., Shanghai Maishi Jingwu Enterprise Management Partnership Enterprise (Limited Partnership), Yao Beier, Niu Zhengxiang and Zhan Hong agreed to acquire additional 5.71% stake in Shanghai Maishi Biotechnology Co., Ltd. from Wu Liang for CNY 1.4 million.	28/23/28	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	18/23/18	CI
Tellgen Corporation Approves Cash Dividend for 2022, Payable on 23 May 2023	16/23/16	CI
Tellgen Corporation Proposes Final Cash Dividend for 2022	25/23/25	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	21/23/21	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	26/22/26	CI
Tellgen Corporation's Equity Buyback announced on October 27, 2021, has expired with 1,062,840 shares, representing 0.65% for CNY 25.43 million.	25/22/25	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	10/22/10	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	19/22/19	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	04/22/04	CI
Tellgen Corporation Announces Final Distribution on A Shares for the Year 2021, Payable on 24 May 2022	18/22/18	CI
Tellgen Corporation Approves Cash Dividend for the Year 2021	17/22/17	CI

Tellgen Corp is a company engaged in research, development, production and sales of in vitro diagnostic reagents and instruments. The Company's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

27/08/2024 - Q2 2024 Earnings Release

More about the company

	1st Jan change	Capi.
TELLGEN CORPORATION	-36.09%	25Cr
BIOMÉRIEUX	-6.66%	1.23TCr
LANTHEUS HOLDINGS, INC.	+90.81%	853.86Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.14%	657.96Cr
DIASORIN S.P.A.	+8.86%	577.28Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-23.82%	348.49Cr
ANDON HEALTH CO., LTD.	+5.12%	254.45Cr
MYRIAD GENETICS, INC.	+43.10%	241.11Cr
VITROLIFE AB	-7.24%	230.05Cr
10X GENOMICS, INC.	-64.26%	207.33Cr

Diagnostic & Testing Substances

Tellgen Corporation

Equities

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

Shareholders Plan To Divest Stake In Tellgen

Latest news about Tellgen Corporation

Chart Tellgen Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances